Genotypic Influences on Network Progression in Parkinson's Disease (NCT04228172)
🩺 Plain-English Summary (8th-Grade Level)
In this longitudinal study, the investigators will follow Parkinson's disease (PD) patients with and without glucocerebrosidase (GBA) mutations. The investigators hypothesize that the rate of increase in brain network activity over time (network progression rate) is faster in patients with GBA gene mutations.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (9 items).
Location: Feinstein Institutes for Medical Research — Manhasset, New York
Age range: 40 Years to 75 Years
🧪 Interventions in This Study
- DNA/GeneticTesting (GENETIC)
- FDG PET scan (RADIATION)
- MRI scan (OTHER)
- Clinical and neuropsychological assessments (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Subjects with pathogenic mutations in LRRK2 related PD mutations (subjects with variants of uncertain significance (VUS) are eligible
- History of known causative factors such as encephalitis or neuroleptic treatment
- Patients with dementia (defined as Mini-Mental Status Exam score \<24 or a Telephone Interview for Cognitive Status score \<26)
- Atypical parkinsonian features including oculomotor abnormalities, incontinence, ataxia, sensory loss, or pyramidal signs
- Known structural brain lesions
- Patients with history of stroke, head injury, high intracranial pressure or severe headaches
- Psychiatric disorder, including a history of major depression in the past 36 months
- Pregnant or breastfeeding women (female subjects of child-bearing potential will be screened for pregnancy before imaging).
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Feinstein Institutes for Medical Research — Manhasset, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson's Disease
- Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics — Boston, Massachusetts
- Non-invasive VNS for Parkinson's Gait — Hines, Illinois
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Phoenix, Arizona
- Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease — New Haven, Connecticut
- Modifiable Variables in Parkinsonism (MVP) — Kenmore, Washington
Explore by condition: All Parkinson's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.